Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities

Molecular Neurobiology

Volumn 49, Issue 3, 2014, Pages 1532-1539

  Zheng, Ping ^a   Shultz, Sandy R ^a   Hovens, Chris M ^a   Velakoulis, Dennis ^b   Jones, Nigel C ^a   O'Brien, Terence J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Acquired epilepsy; Hyperphosphorylated tau; Neuropsychiatric comorbidities; Post status epilepticus; Traumatic brain injury

Indexed keywords

FINGOLIMOD; GLYCOGEN SYNTHASE KINASE 3BETA; HYPERPHOSPHORYLATED TAU PROTEIN; KAINIC ACID; LITHIUM; NEUROLEPTIC AGENT; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; ROSCOVITINE; SELENATE; TAU PROTEIN; UNCLASSIFIED DRUG;

AMNESIA; ATTENTION; BRAIN ATROPHY; COGNITIVE DEFECT; COMORBIDITY; CORTICAL DYSPLASIA; DEPRESSION; DRUG TARGETING; EPILEPSY; EPILEPTIC STATE; EXCITOTOXICITY; EXECUTIVE FUNCTION; FRONTOTEMPORAL DEMENTIA; HUMAN; MEMORY; MENTAL DISEASE; MESIAL TEMPORAL LOBE EPILEPSY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RODENT MODEL; TAUOPATHY; TRAUMATIC BRAIN INJURY; TRAUMATIC EPILEPSY; ANIMAL; MENTAL DISORDERS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; COMORBIDITY; EPILEPSY; HUMANS; MENTAL DISORDERS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84902544067     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8601-9     Document Type: Review

References (82)

1. Hesdorffer DC (2010) The natural history of epilepsy: spontaneous remission and mortality. Epilepsy Curr 10:55-56
2. Yang T, Zhou D, Stefan H (2010) Why mesial temporal lobe epilepsy with hippocampal sclerosis is progressive: uncontrolled inflammation drives disease progression? J Neurol Sci 296:1-6
3. Englander J, Bushnik T, Duong TTet al (2003) Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil 84:365-373 (Pubitemid 36297735)
4. McIntosh AM, Kalnins RM, Mitchell LA et al (2004) Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence. Brain 127:2018-2030 (Pubitemid 39150260)
5. Adams SJ, O'Brien TJ, Lloyd J et al (2008) Neuropsychiatric morbidity in focal epilepsy. Br J Psychiatry 192:464-469 (Pubitemid 351809901)
6. Pitkänen A, Sutula TP (2002) Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 1:173-181 (Pubitemid 37163486)
7. Jensen FE (2011) Epilepsy as a spectrum disorder: implications from novel clinical and basic neuroscience. Epilepsia 52(Suppl 1):1-6
8. Bouilleret V, Hogan RE, Velakoulis D et al (2009) Morphometric abnormalities and hyperanxiety in genetically epileptic rats: a model of psychiatric comorbidity? Neuroimaging 45:267-274
9. Jupp B, Williams J, Binns D et al (2012) Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. Epilepsia 53:1233-1244
10. Helmstaedter C, Elger CE (2009) Chronic temporal lobe epilepsy: a neurodevelopmental or progressively dementing disease? Brain 132:2822-2830
11. Scher WL, Brandt C (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 62:668-700
12. Galanopoulou AS, Buckmaster PS, Staley KJ et al (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571-582
13. Langlois JA, Rutland-Brown W, Wald MM (2005) The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 21:375-378
14. Christine H, James WYC (2012) Treatment of post-traumatic epilepsy. Curr Treat Options Neurol 14:293-306
15. McKee AC, Cantu RC, Nowinski CJ et al (2009) Chronic traumatic encephalopathy in athletes. J Neuropathol Exp Neurol 68:709-735
16. Bales JW, Wagner AK, Kline AE, Dixon CE (2009) Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. Neurosci Biobehav Rev 33:981-1003
17. Rockhill CM, Jaffe K, Zhou C et al (2012) Health care costs associated with traumatic brain injury and psychiatric illness in adults. J Neurotrauma 29:1038-1046
18. Warriner EM, Velikonja D (2006) Psychiatric disturbances after traumatic brain injury: neurobehavioral and personality changes. Curr Psychiatry Rep 8:73-80
19. McIntosh TK (1994) Neurochemical sequelae of traumatic brain injury: therapeutic implications. Cerebrovasc Brain Metab Rev 6:109-162
20. Johnston MV (2005) Excitotoxicity in perinatal brain injury. Brain Pathol 15:234-240
21. Hall ED, Vaishnav RA, Mustafa AG (2010) Antioxidant therapies for traumatic brain injury. Neurotherapeutics 7:51-61
22. Whitney NP, Eidem TM, Peng H et al (2009) Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem 108:1343-1359
23. Park E, Bell JD, Baker AJ (2008) Traumatic brain injury: can the consequences be stopped? CMAJ 178:1163-1170 (Pubitemid 351596226)
24. Schoch KM, Madathil SK, Saatman KE (2012) Genetic manipulation of cell death and neuroplasticity pathways in traumatic brain injury. Neurotherapeutics 9:323-337
25. Tran HT, LaFerla FM, Holtzman DM, Brody DL (2011) Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-{beta} accumulation and independently accelerates the development of tau abnormalities. J Neurosci 31:9513-9525
26. Uryu K, Chen X-H, Martinez D et al (2007) Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 208:185-192 (Pubitemid 350101496)
27. Sivanandam TM, Thakur MK (2012) Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev 36:1376-1381
28. Lee PC, Bordelon Y, Bronstein J, Ritz B (2012) Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology 79:2061-2066
29. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6:464-479 (Pubitemid 47064569)
30. Palop J, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66:435-440
31. Engel T, Goñi-Oliver P, Lucas J et al (2006) Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99:1445-1455 (Pubitemid 44924224)
32. Irizarry MC, Jin S, He F et al (2012) Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 69:368-372
33. Lee S, Hall GF, Shea TB (2011) Potentiation of tau aggregation by cdk5 and GSK3β. J Alzheimers Dis 26:355-364
34. Liang Z, Liu F, Iqbal K et al (2009) Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis 17:531-539
35. Morris M, Koyama A, Masliah E, Mucke L (2011) Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS ONE 6:e29257
36. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672 (Pubitemid 47283144)
37. Martin L, Latypova X, Terro F (2011) Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 58:458-471
38. Brunden KR, Trojanowski JQ, Lee VMY (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related taupathies. Nat Rev Drug Discov 8:783-793
39. Noble W, Planel E, Zehr C et al (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102:6990-6995 (Pubitemid 40675429)
40. Leroy K, Ando K, Héraud C et al (2010) Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 19:705-719
41. Serenó L, Coma M, Rodríguez M et al (2009) A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359-367
42. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112-119
43. Cruz J, Tseng HC, Goldman JA et al (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483 (Pubitemid 37494698)
44. Braithwaite SP, Stock JB, Lombroso PJ, Nairn AC (2012) Protein phosphatases and Alzheimer's disease. Prog Mol Biol Transl Sci 106:343-379
45. Gong CX, Shaikh S, Wang JZ et al (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65:732-738
46. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22:1942-1950 (Pubitemid 41579384)
47. Hanyu Y, Imai KK, Kawasaki Y et al (2009) Schizosaccharomyces pombe cell division cycle under limited glucose requires Ssp1 kinase, the putative CaMK, and Sds23, a PP2A-related phosphatase inhibitor. Genes Cells 14:539-554
48. Dickey AS, Strack S (2011) PKA/AKAP1 and PP2A/Bβ2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. J Neurosci 31:15716-15726
49. Liu XP, Zheng HY, Qu M et al (2012) Upregulation of astrocytes protein phosphatase-2A stimulates astrocytes migration via inhibiting p38 MAPK in tg2576 mice. Glia 60:1279-1288
50. Jeong HS, Park KC, Kim DS (2012) PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation. Mol Cell Biochem 367:43-49
51. Gavett BE, Stern RA, Cantu RC et al (2010) Mild traumatic brain injury: a risk factor for neurodegeneration. Alzheimers Res Ther 2:18
52. Xiong Y, Mahmood A, Chopp M (2013) Animal models of traumatic brain injury. Nat Rev Neurosci 14:128-142
53. Magnoni S, Esparza TJ, Conte V et al (2012) Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain 135:1268-1280
54. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4:13
55. Guillozet AL, Weintraub S, Mash DC et al (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. JAMA Neurol 60:729-736 (Pubitemid 36569891)
56. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70:410-426
57. Deters N, Ittner LM, Gotz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun 379:400-405
58. Walaas SI, Hemmings HC, Greengard P, Nairn AC (2011) Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases. Front Neuroanat 5:1-17
59. Roberson ED, Scearce-Levie K, Palop J et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754 (Pubitemid 46717684)
60. Zhao S, Fu J, Liu X et al (2012) Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats. Neurol Res 34:400-407
61. Kabadi SV, Stoica BA, Hanscom M et al (2012) CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. Neurotherapeutics 9:405-421
62. Wu PR, Tsai PI, Chen GC et al (2011) DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity. Cell Death Differ 18:1507-1520
63. Medders KE, Kaul M (2011) Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. J Neuroimmune Pharm 6:202-215
64. Honig A, Arts BM, Ponds RW, Riedel WJ (1999) Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. Int Clin Psychopharmacol 14:167-171 (Pubitemid 29348769)
65. Pachet AK, Wisniewski AMA (2003) The effects of lithium on cognition: an updated review. Psychopharmacology (Berlin) 170:225-234 (Pubitemid 37491601)
66. Hilton GD, Stoica BA, Byrnes KR, Faden AI (2008) Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 28:1845-1859
67. Kabadi SV, Stoica BA, Byrnes KR et al (2011) Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma. J Cereb Blood Flow Metab 32:137-149
68. Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417-439 (Pubitemid 32158309)
69. Sontag E, Luangpirom A, Hladik C et al (2004) Altered expression levels of the protein phosphatase 2A AB[alpha]C enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63:287
70. Xu Y, Chen Y, Zhang P et al (2008) Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell 31:873-885
71. Shi YY (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139:468-484
72. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168:402-412 (Pubitemid 32289776)
73. Iqbal K, del Alonso A, Chen S et al (2005) Tau pathology in Alzheimer disease and other tauopathies. Acta Bioenerg 1739:198-210 (Pubitemid 40018538)
74. Ramírez-Munguía N, Vera G, Tapia R (2003) Epilepsy, neurodegeneration, and extracellular glutamate in the hippocampus of awake and anesthetized rats treated with okadaic acid. Neurochem Res 28:1517-1524 (Pubitemid 37193533)
75. Zhang Z, Simpkins JW (2010) An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 1359:233-246
76. Tian FF, Zeng C, Ma YF et al (2010) Potential roles of Cdk5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model. Clin Lab 56:127-136
77. Corcoran NM, Hovens CM (2010) Activating PP2A as a therapeutic intervention strategy in Alzheimer's disease. In: Martinez (ed) Emerging drugs and targets for Alzheimer's disease, 1st edn. Royal Society of Chemistry, London, pp 195-209
78. Curia G, Levitt M, Fender JS et al (2011) Impact of injury location and severity on posttraumatic epilepsy in the rat: role of frontal neocortex. Cereb Cortex 21:1574-1592
79. Jones NC, Nguyen T, Corcoran NM et al (2011) Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol Dis 45:897-901
80. Brinkmann V, Billich A, Baumruker T et al (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883-897
81. Yang Y, Huang Q, Lu YJ et al (2012) Reactivating PP2A by FTY 720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 113:1314-1322
82. Foster CA, Howard LM, Schweitzer A et al (2007) Brain penetration of the oral immunomodulatory drug FTY 720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469-475